{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T04:34:42Z","timestamp":1763613282734,"version":"3.45.0"},"reference-count":129,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRR"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Autoimmune diseases are a class of diseases wherein the immune system of the body\ntargets itself through autoreactive T cells and autoantibodies. Autoimmune diseases are classified\nas organ-specific autoimmune diseases and systemic autoimmune diseases. Organ-specific autoimmune\ndiseases such as primary biliary cirrhosis, Hashimoto's Thyroiditis (HT), Type 1 Diabetes\nmellitus (T1D), and Graves' Disease (GD) are characterized by a unique immune system response\nto autoantigens in a single organ. Systemic autoimmune diseases such as Systemic Lupus Erythematosus\n(SLE), Rheumatoid Arthritis (RA), and Sjogren syndrome are characterized by a systemic\nspread of autoantigens causing a multi-organ attack. In this review, we discuss rheumatoid\narthritis, its prevalence in India, and its risk factors. We discuss the pharmacotherapies for RA that\nare currently available on the market. By identifying the disadvantages and side effects of the treatment,\nwe mainly focus on how nanotechnology will be helpful in vaccine research and the advancement\nof anti-RA therapeutics from vaccines to nano-vaccines. In addition, the benefits of\nnano-vaccines are explored in future perspectives. In conclusion, nano-vaccines will be a novel\ntechnique for treating RA because they show possible outcomes from nanovaccine use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115733971330575250121054355","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T03:02:20Z","timestamp":1741748540000},"page":"519-534","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vaccine to Nano-Vaccine: Novel Technique to Treat Rheumatoid Arthritis"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9982-0014","authenticated-orcid":true,"given":"Sandip","family":"Zine","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, SVKMs Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5605-6904","authenticated-orcid":true,"given":"Dhanashri","family":"Kadam","sequence":"additional","affiliation":[{"name":"Pharmaceutical Analysis, SVKMs Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5481-6526","authenticated-orcid":true,"given":"Pranita","family":"Lodha","sequence":"additional","affiliation":[{"name":"Pharmaceutical Analysis, SVKMs Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2017016067","volume":"34","author":"Rahman M.","year":"2017","unstructured":"Rahman M.; Beg S.; Anwar F.; Kumar V.; Ubale R.; Addo R.T.; Ali R.; Akhter S.; Liposome-based nanomedicine therapeutics for rheumatoid arthritis. Crit Rev Ther Drug Carrier Syst  2017,34(4),283-316","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/rheumatology\/41.7.793","volume":"41","author":"Symmons D.","year":"2002","unstructured":"Symmons D.; Turner G.; Webb R.; Asten P.; Barrett E.; Lunt M.; Scott D.; Silman A.; The prevalence of rheumatoid arthritis in the United Kingdom: New estimates for a new century. Br J Rheumatol  2002,41(7),793-800","journal-title":"Br J Rheumatol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/ard.58.7.399","volume":"58","author":"Van Royen B.J.","year":"1999","unstructured":"Van Royen B.J.; De Gast A.; Lumbar osteotomy for correction of thoracolumbar kyphotic deformity in ankylosing spondylitis. A structured review of three methods of treatment. Ann Rheum Dis  1999,58(7),399-406","journal-title":"Ann Rheum Dis"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jconrel.2021.09.037","volume":"339","author":"Dangkoub F.","year":"2021","unstructured":"Dangkoub F.; Sankian M.; Tafaghodi M.; Jaafari M.R.; Badiee A.; The impact of nanocarriers in the induction of antigen-specific immunotolerance in autoimmune diseases. J Control Release  2021,339,274-283","journal-title":"J Control Release"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1136\/ard.2010.131730","volume":"69","author":"Gibofsky A.","year":"2010","unstructured":"Gibofsky A.; Yazici Y.; Treatment of rheumatoid arthritis: Strategies for achieving optimal outcomes. Ann Rheum Dis  2010,69(6),941-942","journal-title":"Ann Rheum Dis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/1756-185X.12621","volume":"19","author":"Handa R.","year":"2016","unstructured":"Handa R.; Rao U.R.K.; Lewis J.F.M.; Rambhad G.; Shiff S.; Ghia C.J.; Literature review of rheumatoid arthritis in India. Int J Rheum Dis  2016,19(5),440-451","journal-title":"Int J Rheum Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","volume":"376","author":"Scott D.L.","year":"2010","unstructured":"Scott D.L.; Wolfe F.; Huizinga T.W.J.; Rheumatoid arthritis. Lancet  2010,376(9746),1094-1108","journal-title":"Lancet"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.berh.2010.10.001","volume":"24","author":"Carmona L.","year":"2010","unstructured":"Carmona L.; Cross M.; Williams B.; Lassere M.; March L.; Rheumatoid arthritis. Best Pract Res Clin Rheumatol  2010,24(6),733-745","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/clinpract12040062","volume":"12","author":"Dar W.R.","year":"2022","unstructured":"Dar W.R.; Mir I.A.; Siddiq S.; Nadeem M.; Singh G.; The assessment of fatigue in rheumatoid arthritis patients and its impact on their quality of life. Clin Pract  2022,12(4),591-598","journal-title":"Clin Pract"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/S0140-6736(20)32340-0","volume":"396","author":"Cieza A.","year":"2020","unstructured":"Cieza A.; Causey K.; Kamenov K.; Hanson S.W.; Chatterji S.; Vos T.; Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet  2020,396(10267),2006-2017","journal-title":"Lancet"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2174\/1573397118666220804162313","volume":"19","author":"Garg A.","year":"2023","unstructured":"Garg A.; Garg R.; The research trends and scientometric assessment of rheumatoid arthritis in India during 2016-2021. Curr Rheumatol Rev  2023,19(1),26-35","journal-title":"Curr Rheumatol Rev"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.biopha.2006.09.003","volume":"60","author":"Orozco G.","year":"2006","unstructured":"Orozco G.; Rueda B.; Martin J.; Genetic basis of rheumatoid arthritis. Biomed Pharmacother  2006,60(10),656-662","journal-title":"Biomed Pharmacother"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1016\/j.vaccine.2018.04.062","volume":"36","author":"Zhang N.","year":"2018","unstructured":"Zhang N.; Nandakumar K.S.; Recent advances in the development of vaccines for chronic inflammatory autoimmune diseases. Vaccine  2018,36(23),3208-3220","journal-title":"Vaccine"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ajhg.2012.08.026","volume":"91","author":"Morris D.L.","year":"2012","unstructured":"Morris D.L.; Taylor K.E.; Fernando M.M.A.; Nititham J.; Alarc&#xF3;n-Riquelme M.E.; Barcellos L.F.; Behrens T.W.; Cotsapas C.; Gaffney P.M.; Graham R.R.; Pons-Estel B.A.; Gregersen P.K.; Harley J.B.; Hauser S.L.; Hom G.; Langefeld C.D.; Noble J.A.; Rioux J.D.; Seldin M.F.; Criswell L.A.; Vyse T.J.; Unraveling multiple MHC gene associations with systemic lupus erythematosus: Model choice indicates a role for HLA alleles and non-HLA genes in Europeans. Am J Hum Genet  2012,91(5),778-793","journal-title":"Am J Hum Genet"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1002\/art.20553","volume":"50","author":"Padyukov L.","year":"2004","unstructured":"Padyukov L.; Silva C.; Stolt P.; Alfredsson L.; Klareskog L.; A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum  2004,50(10),3085-3092","journal-title":"Arthritis Rheum"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nri.2016.124","volume":"17","author":"Malmstr&#xF6;m V.","year":"2017","unstructured":"Malmstr&#xF6;m V.; Catrina A.I.; Klareskog L.; The immunopathogenesis of seropositive rheumatoid arthritis: From triggering to targeting. Nat Rev Immunol  2017,17(1),60-75","journal-title":"Nat Rev Immunol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1007165","DOI":"10.3389\/fimmu.2022.1007165","volume":"13","author":"Zhao T.","year":"2022","unstructured":"Zhao T.; Wei Y.; Zhu Y.; Xie Z.; Hai Q.; Li Z.; Qin D.; Gut microbiota and rheumatoid arthritis: From pathogenesis to novel therapeutic opportunities. Front Immunol  2022,13,1007165","journal-title":"Front Immunol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0002-9343(85)90237-2","volume":"78","author":"McDuffie F.C.","year":"1985","unstructured":"McDuffie F.C.; Morbidity impact of rheumatoid arthritis on society. Am J Med  1985,78(1),1-5","journal-title":"Am J Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/art.11171","volume":"48","author":"Blaschke S.","year":"2003","unstructured":"Blaschke S.; Middel P.; Dorner B.G.; Blaschke V.; Hummel K.M.; Kroczek R.A.; Reich K.; Benoehr P.; Koziolek M.; M&#xFC;ller G.A.; Expression of activation-induced, T cell-derived, and chemokine-related cytokine\/lymphotactin and its functional role in rheumatoid arthritis. Arthritis Rheum  2003,48(7),1858-1872","journal-title":"Arthritis Rheum"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1021\/mp2000742","volume":"8","author":"van den Hoven J.M.","year":"2011","unstructured":"van den Hoven J.M.; Van Tomme S.R.; Metselaar J.M.; Nuijen B.; Beijnen J.H.; Storm G.; Liposomal drug formulations in the treatment of rheumatoid arthritis. Mol Pharm  2011,8(4),1002-1015","journal-title":"Mol Pharm"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3109\/21691401.2015.1129617","volume":"44","author":"Rahman M.","year":"2016","unstructured":"Rahman M.; Kumar V.; Beg S.; Sharma G.; Katare O.P.; Anwar F.; Emergence of liposome as targeted magic bullet for inflammatory disorders: Current state of the art. Artif Cells Nanomed Biotechnol  2016,44(7),1597-1608","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1574891X1101160511195513","volume":"11","author":"Rahman M.","year":"2016","unstructured":"Rahman M.; Beg S.; Sharma G.; Saini S.; Rub R.A.; Aneja P.; Anwar F.; Alam M.A.; Kumar V.; Lipid-based vesicular nanocargoes as nanotherapeutic targets for the effective management of rheumatoid arthritis. Recent Pat Antiinfect Drug Discov  2016,11(1),3-15","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1124\/pr.114.009639","volume":"67","author":"Siebert S.","year":"2015","unstructured":"Siebert S.; Tsoukas A.; Robertson J.; McInnes I.; Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev  2015,67(2),280-309","journal-title":"Pharmacol Rev"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2741\/1817","volume":"11","author":"Burrage P.S.","year":"2006","unstructured":"Burrage P.S.; Mix K.S.; Brinckerhoff C.E.; Matrix metalloproteinases: Role in arthritis. Front Biosci  2006,11(1),529-543","journal-title":"Front Biosci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.freeradbiomed.2016.06.020","volume":"97","author":"Khojah H.M.","year":"2016","unstructured":"Khojah H.M.; Ahmed S.; Abdel-Rahman M.S.; Hamza A.B.; Reactive oxygen and nitrogen species in patients with rheumatoid arthritis as potential biomarkers for disease activity and the role of antioxidants. Free Radic Biol Med  2016,97,285-291","journal-title":"Free Radic Biol Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/BF01857226","volume":"10","author":"Mannik M.","year":"1988","unstructured":"Mannik M.; Nardella F.A.; Sasso E.H.; Rheumatoid factors in immune complexes of patients with rheumatoid arthritis. Springer Semin Immunopathol  1988,10(2-3),215-230","journal-title":"Springer Semin Immunopathol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.autrev.2009.11.017","volume":"9","author":"Conrad K.","year":"2010","unstructured":"Conrad K.; Roggenbuck D.; Reinhold D.; D&#xF6;rner T.; Profiling of rheumatoid arthritis associated autoantibodies. Autoimmun Rev  2010,9(6),431-435","journal-title":"Autoimmun Rev"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.2146\/ajhp050514","volume":"63","author":"Gaffo A.","year":"2006","unstructured":"Gaffo A.; Saag K.G.; Curtis J.R.; Treatment of rheumatoid arthritis. Am J Health Syst Pharm  2006,63(24),2451-2465","journal-title":"Am J Health Syst Pharm"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/BOR.0000000000000153","volume":"27","author":"Sethi M.K.","year":"2015","unstructured":"Sethi M.K.; O\u2019Dell J.R.; Combination conventional DMARDs compared to biologicals. Curr Opin Rheumatol  2015,27(2),183-188","journal-title":"Curr Opin Rheumatol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/ard.2009.127225","volume":"69","author":"Gaujoux-Viala C.","year":"2010","unstructured":"Gaujoux-Viala C.; Smolen J.S.; Landew&#xE9; R.; Dougados M.; Kvien T.K.; Mola E.M.; Scholte-Voshaar M.; van Riel P.; Gossec L.; Current evidence for the management of rheumatoid arthritis with synthetic disease- modifying antirheumatic drugs: A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis  2010,69(6),1004-1009","journal-title":"Ann Rheum Dis"},{"key":"ref=31","first-page":"216","volume":"33","author":"Lampropoulos C.E.","year":"2015","unstructured":"Lampropoulos C.E.; Orfanos P.; Bournia V.K.; Karatsourakis T.; Mavragani C.; Pikazis D.; Manoussakis M.N.; Tzioufas A.G.; Moutsopoulos H.M.; Vlachoyiannopoulos P.G.; Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: A real world study. Clin Exp Rheumatol  2015,33(2),216-224","journal-title":"Clin Exp Rheumatol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/1759720X17752037","volume":"10","author":"McCarty D.","year":"2018","unstructured":"McCarty D.; Robinson A.; Efficacy and safety of sarilumab in patients with active rheumatoid arthritis. Ther Adv Musculoskelet Dis  2018,10(3),61-67","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1093\/rheumatology\/kex245","volume":"56","year":"2017","unstructured":"FDA issues concerns about optimal baricitinib doses for the treatment of moderate-to-severe rheumatoid arthritis and delays drug approval. Rheumatology (Oxford)  2017,56(8),e22-e22","journal-title":"Rheumatology (Oxford)"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.clinthera.2014.06.018","volume":"36","author":"Kaur K.","year":"2014","unstructured":"Kaur K.; Kalra S.; Kaushal S.; Systematic review of tofacitinib: A new drug for the management of rheumatoid arthritis. Clin Ther  2014,36(7),1074-1086","journal-title":"Clin Ther"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","volume":"78","author":"Keam S.J.","year":"2018","unstructured":"Keam S.J.; Inotersen: First global approval. Drugs  2018,78(13),1371-1376","journal-title":"Drugs"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"e01371","DOI":"10.1002\/brb3.1371","volume":"9","author":"Gertz M.A.","year":"2019","unstructured":"Gertz M.A.; Mauermann M.L.; Grogan M.; Coelho T.; Advances in the treatment of hereditary transthyretin amyloidosis: A review. Brain Behav  2019,9(9),e01371","journal-title":"Brain Behav"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.3390\/ijms22031022","volume":"22","author":"Makalish T.P.","year":"2021","unstructured":"Makalish T.P.; Golovkin I.O.; Oberemok V.V.; Laikova K.V.; Temirova Z.Z.; Serdyukova O.A.; Novikov I.A.; Rosovskyi R.A.; Gordienko A.I.; Zyablitskaya E.Y.; Gafarova E.A.; Yurchenko K.A.; Fomochkina I.I.; Kubyshkin A.V.; Anti-rheumatic effect of antisense oligonucleotide Cytos-11 targeting TNF-&#x3B1; expression. Int J Mol Sci  2021,22(3),1022","journal-title":"Int J Mol Sci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/ar4174","volume":"15","author":"Crofford L.J.","year":"2013","unstructured":"Crofford L.J.; Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther  2013,15(S3)(Suppl. 3),S2","journal-title":"Arthritis Res Ther"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40265-015-0392-z","volume":"75","author":"Altman R.","year":"2015","unstructured":"Altman R.; Bosch B.; Brune K.; Patrignani P.; Young C.; Advances in NSAID development: Evolution of diclofenac products using pharmaceutical technology. Drugs  2015,75(8),859-877","journal-title":"Drugs"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3389\/fphar.2017.00460","volume":"8","author":"Li P.","year":"2017","unstructured":"Li P.; Zheng Y.; Chen X.; Drugs for autoimmune inflammatory diseases: From small molecule compounds to anti-TNF biologics. Front Pharmacol  2017,8,460","journal-title":"Front Pharmacol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"885","DOI":"10.2174\/1567201817666200724170203","volume":"17","author":"Anjum F.","year":"2020","unstructured":"Anjum F.; Zakir F.; Verma D.; Aqil M.; Singh M.; Jain P.; Mirza M.A.; Anwer M.K.; Iqbal Z.; Exploration of nanoethosomal transgel of naproxen sodium for the treatment of arthritis. Curr Drug Deliv  2020,17(10),885-897","journal-title":"Curr Drug Deliv"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s10787-018-00557-2","volume":"27","author":"Rezaieyazdi Z.","year":"2019","unstructured":"Rezaieyazdi Z.; Farooqi A.; Soleymani-Salehabadi H.; Ahmadzadeh A.; Aslani M.; Omidian S.; Sadoughi A.; Vahidi Z.; Khodashahi M.; Zamurrad S.; Mortazavi-Jahromi S.S.; Fallahzadeh H.; Hosseini M.; Aghazadeh Z.; Ekhtiari P.; Matsuo H.; Rehm B.H.A.; Cuzzocrea S.; D\u2019Aniello A.; Mirshafiey A.; International multicenter randomized, placebo-controlled phase III clinical trial of &#x3B2;-d-mannuronic acid in rheumatoid arthritis patients. Inflammopharmacology  2019,27(5),911-921","journal-title":"Inflammopharmacology"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.pharep.2017.01.021","volume":"69","author":"Mortazavi-Jahromi S.S.","year":"2017","unstructured":"Mortazavi-Jahromi S.S.; Jamshidi M.M.; Farazmand A.; Aghazadeh Z.; Yousefi M.; Mirshafiey A.; Pharmacological effects of &#x3B2;-d-mannuronic acid (M2000) on miR-146a, IRAK1, TRAF6 and NF-&#x3BA;B gene expression, as target molecules in inflammatory reactions. Pharmacol Rep  2017,69(3),479-484","journal-title":"Pharmacol Rep"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"e000889","DOI":"10.1136\/rmdopen-2018-000889","volume":"5","author":"Buttgereit F.","year":"2019","unstructured":"Buttgereit F.; Strand V.; Lee E.B.; Simon-Campos A.; McCabe D.; Genet A.; Tammara B.; Rojo R.; Hey-Hadavi J.; Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: A randomised, double-blind, multicentre, phase IIb study. RMD Open  2019,5(1),e000889","journal-title":"RMD Open"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1039\/C9TB02538C","volume":"8","author":"Wang Q.","year":"2020","unstructured":"Wang Q.; He L.; Fan D.; Liang W.; Fang J.; Improving the anti-inflammatory efficacy of dexamethasone in the treatment of rheumatoid arthritis with polymerized stealth liposomes as a delivery vehicle. J Mater Chem B Mater Biol Med  2020,8(9),1841-1851","journal-title":"J Mater Chem B Mater Biol Med"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s40267-020-00755-5","volume":"36","author":"Yoshii I.","year":"2020","unstructured":"Yoshii I.; Sawada N.; Efficacy and safety of intra-articular injection with triamcinolone acetonide for patients with rheumatoid arthritis. Drugs Ther Perspect  2020,36(9),404-412","journal-title":"Drugs Ther Perspect"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"e0248866","DOI":"10.1371\/journal.pone.0248866","volume":"16","author":"Paglia M.D.G.","year":"2021","unstructured":"Paglia M.D.G.; Silva M.T.; Lopes L.C.; Barberato-Filho S.; Mazzei L.G.; Abe F.C.; de C&#xE1;ssia Bergamaschi C.; Use of corticoids and non-steroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review and network meta-analysis. PLoS One  2021,16(4),e0248866","journal-title":"PLoS One"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1179573519831997","DOI":"10.1177\/1179573519831997","volume":"11","author":"Akg&#xFC;n K.","year":"2019","unstructured":"Akg&#xFC;n K.; Essner U.; Seydel C.; Ziemssen T.; Daily practice managing resistant multiple sclerosis spasticity with delta-9-tetrahydrocannabinol: Cannabidiol oromucosal spray: A systematic review of observational studies. J Cent Nerv Syst Dis  2019,11,1179573519831997","journal-title":"J Cent Nerv Syst Dis"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"91","DOI":"10.5152\/eurjrheum.2015.0028","volume":"3","author":"Sames E.","year":"2016","unstructured":"Sames E.; Paterson H.; Li C.; Hydroxychloroquine-induced agranulocytosis in a patient with long-term rheumatoid arthritis. Eur J Rheumatol  2016,3(2),91-92","journal-title":"Eur J Rheumatol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.3899\/jrheum.170158","volume":"44","author":"Kim J.W.","year":"2017","unstructured":"Kim J.W.; Kim Y.Y.; Lee H.; Park S.H.; Kim S.K.; Choe J.Y.; Risk of retinal toxicity in longterm users of hydroxychloroquine. J Rheumatol  2017,44(11),1674-1679","journal-title":"J Rheumatol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"A32","DOI":"10.1016\/j.cgh.2011.09.027","volume":"10","author":"DeMichele J.","year":"2012","unstructured":"DeMichele J.; Rezaizadeh H.; Goldstein J.I.; Sulfasalazine crystalluria-induced anuric renal failure. Clin Gastroenterol Hepatol  2012,10(2),A32","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1080\/0886022X.2017.1399908","volume":"39","author":"Niknahad H.","year":"2017","unstructured":"Niknahad H.; Heidari R.; Mohammadzadeh R.; Ommati M.M.; Khodaei F.; Azarpira N.; Abdoli N.; Zarei M.; Asadi B.; Rasti M.; Shirazi Yeganeh B.; Taheri V.; Saeedi A.; Najibi A.; Sulfasalazine induces mitochondrial dysfunction and renal injury. Ren Fail  2017,39(1),745-753","journal-title":"Ren Fail"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1093\/ndt\/gfp277","volume":"24","author":"Augusto J.F.","year":"2009","unstructured":"Augusto J.F.; Sayegh J.; Simon A.; Croue A.; Chennebault J.M.; Cousin M.; Subra J.F.; A case of sulphasalazine-induced DRESS syndrome with delayed acute interstitial nephritis. Nephrol Dial Transplant  2009,24(9),2940-2942","journal-title":"Nephrol Dial Transplant"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jbspin.2018.07.004","volume":"86","author":"Friedman B.","year":"2019","unstructured":"Friedman B.; Cronstein B.; Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine  2019,86(3),301-307","journal-title":"Joint Bone Spine"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.3390\/ijms20205023","volume":"20","author":"Bedoui Y.","year":"2019","unstructured":"Bedoui Y.; Guillot X.; S&#xE9;lambarom J.; Guiraud P.; Giry C.; Jaffar-Bandjee M.C.; Ralandison S.; Gasque P.; Methotrexate an old drug with new tricks. Int J Mol Sci  2019,20(20),5023","journal-title":"Int J Mol Sci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ejmech.2018.09.027","volume":"158","author":"Wang W.","year":"2018","unstructured":"Wang W.; Zhou H.; Liu L.; Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. Eur J Med Chem  2018,158,502-516","journal-title":"Eur J Med Chem"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1182\/bloodadvances.2017007526","volume":"1","author":"Broglie L.","year":"2017","unstructured":"Broglie L.; Pommert L.; Rao S.; Thakar M.; Phelan R.; Margolis D.; Talano J.; Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. Blood Adv  2017,1(19),1533-1536","journal-title":"Blood Adv"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/14656566.2020.1739649","volume":"21","author":"Tanaka Y.","year":"2020","unstructured":"Tanaka Y.; Izutsu H.; Peficitinib for the treatment of rheumatoid arthritis: An overview from clinical trials. Expert Opin Pharmacother  2020,21(9),1015-1025","journal-title":"Expert Opin Pharmacother"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0149-2918(04)90048-3","volume":"26","author":"Li E.","year":"2004","unstructured":"Li E.; Tam L.S.; Tomlinson B.; Leflunomide in the treatment of rheumatoid arthritis. Clin Ther  2004,26(4),447-459","journal-title":"Clin Ther"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.semarthrit.2019.06.009","volume":"50","author":"Cui X.","year":"2020","unstructured":"Cui X.; Dai X.; Ma L.; Yang C.; Tan W.; Zhang L.; Zhang Z.; Feng X.; Wu R.; Zou Y.; Zhou Z.; Lu Y.; Wang Y.; Wu M.; Li S.; Wang L.; Lin H.; Dong Z.; Fu W.; Sun X.; Wang C.; Ding J.; Lv P.; Lin J.; Jiang L.; Efficacy and safety of leflunomide treatment in Takayasu arteritis: Case series from the East China cohort. Semin Arthritis Rheum  2020,50(1),59-65","journal-title":"Semin Arthritis Rheum"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4103\/0019-5359.26608","volume":"60","author":"Jose V.M.","year":"2006","unstructured":"Jose V.M.; Paul B.J.; Thomas T.; Antony T.; Efficacy and safety of leflunomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis. Indian J Med Sci  2006,60(8),318-326","journal-title":"Indian J Med Sci"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"5238","DOI":"10.3390\/ijms21155238","volume":"21","author":"Pandolfi F.","year":"2020","unstructured":"Pandolfi F.; Franza L.; Carusi V.; Altamura S.; Andriollo G.; Nucera E.; Interleukin-6 in rheumatoid arthritis. Int J Mol Sci  2020,21(15),5238","journal-title":"Int J Mol Sci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.biomaterials.2017.01.008","volume":"122","author":"Wang Q.","year":"2017","unstructured":"Wang Q.; Jiang H.; Li Y.; Chen W.; Li H.; Peng K.; Zhang Z.; Sun X.; Targeting NF-kB signaling with polymeric hybrid micelles that co-deliver siRNA and dexamethasone for arthritis therapy. Biomaterials  2017,122,10-22","journal-title":"Biomaterials"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/DDDT.S150580","volume":"13","author":"Biggioggero M.","year":"2018","unstructured":"Biggioggero M.; Crotti C.; Becciolini A.; Favalli E.G.; Tocilizumab in the treatment of rheumatoid arthritis: An evidence-based review and patient selection. Drug Des Devel Ther  2018,13,57-70","journal-title":"Drug Des Devel Ther"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2217\/imt-2017-0075","volume":"10","author":"Lee E.B.","year":"2018","unstructured":"Lee E.B.; A review of sarilumab for the treatment of rheumatoid arthritis. Immunotherapy  2018,10(1),57-65","journal-title":"Immunotherapy"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2147\/DDDT.S100302","volume":"11","author":"Raimondo M.G.","year":"2017","unstructured":"Raimondo M.G.; Biggioggero M.; Crotti C.; Becciolini A.; Favalli e.g.; Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Devel Ther  2017,11,1593-1603","journal-title":"Drug Des Devel Ther"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5152\/eurjrheum.2021.19207","volume":"8","author":"Genovese M.C.","year":"2021","unstructured":"Genovese M.C.; Durez P.; Fleischmann R.; Tanaka Y.; Furst D.; Yamanaka H.; Korneva E.; Vasyutin I.; Takeuchi T.; Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies. Eur J Rheumatol  2021,8(3),120-129","journal-title":"Eur J Rheumatol"},{"key":"ref=68","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab247.126","volume":"60","author":"Feist E.","year":"2021","unstructured":"Feist E.; Chohan S.; Fatenejad S.; Grishin S.; P131\u2003Efficacy and safety of olokizumab in a phase III trial of patients with moderately to severely active RA inadequately controlled by methotrexate: Placebo and active controlled study. Br J Rheumatol  2021,60(Supplement_1)","journal-title":"Br J Rheumatol"},{"key":"ref=69","first-page":"101","volume":"1","author":"Sekhon B.S.","year":"2011","unstructured":"Sekhon B.S.; Saluja V.; Nanovaccines-an overview. Int J PharmaFrontRes  2011,1(1),101-109","journal-title":"Int J PharmaFrontRes"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1586\/14760584.2015.1026330","volume":"14","author":"Rosenthal K.S.","year":"2015","unstructured":"Rosenthal K.S.; Mikecz K.; Steiner H.L.; Glant T.T.; Finnegan A.; Carambula R.E.; Zimmerman D.H.; Rheumatoid arthritis vaccine therapies: Perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis. Expert Rev Vaccines  2015,14(6),891-908","journal-title":"Expert Rev Vaccines"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.virusres.2007.03.025","volume":"133","author":"Roberts A.","year":"2008","unstructured":"Roberts A.; Lamirande E.W.; Vogel L.; Jackson J.P.; Paddock C.D.; Guarner J.; Zaki S.R.; Sheahan T.; Baric R.; Subbarao K.; Animal models and vaccines for SARS-CoV infection. Virus Res  2008,133(1),20-32","journal-title":"Virus Res"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.vaccine.2008.11.090","volume":"27","author":"Xinqiang S.","year":"2009","unstructured":"Xinqiang S.; Fei L.; Nan L.; Yuan L.; Hong X.; Fang Y.; Liuxin T.; Yuying S.; Caixi X.; Yongzhi X.; Construction and characterization of a novel DNA vaccine that is potent antigen-specific tolerizing therapy for experimental arthritis by increasing CD4+CD25+Treg cells and inducing Th1 to Th2 shift in both cells and cytokines. Vaccine  2009,27(5),690-700","journal-title":"Vaccine"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.imlet.2008.11.013","volume":"122","author":"Wraith D.C.","year":"2009","unstructured":"Wraith D.C.; Therapeutic peptide vaccines for treatment of autoimmune diseases. Immunol Lett  2009,122(2),134-136","journal-title":"Immunol Lett"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/08830180500371256","volume":"24","author":"Sospedra M.","year":"2005","unstructured":"Sospedra M.; Martin R.; Antigen-specific therapies in multiple sclerosis. Int Rev Immunol  2005,24(5-6),393-413","journal-title":"Int Rev Immunol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3109\/s10165-009-0174-0","volume":"19","author":"Wakamatsu E.","year":"2009","unstructured":"Wakamatsu E.; Matsumoto I.; Yoshiga Y.; Hayashi T.; Goto D.; Ito S.; Sumida T.; Altered peptide ligands regulate type II collagen-induced arthritis in mice. Mod Rheumatol  2009,19(4),366-371","journal-title":"Mod Rheumatol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.4049\/jimmunol.176.3.1525","volume":"176","author":"Dzhambazov B.","year":"2006","unstructured":"Dzhambazov B.; Nandakumar K.S.; Kihlberg J.; Fugger L.; Holmdahl R.; Vestberg M.; Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules. J Immunol  2006,176(3),1525-1533","journal-title":"J Immunol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1191\/0961203305lu2239oa","volume":"14","author":"Li Z-G.","year":"2005","unstructured":"Li Z-G.; Mu R.; Dai Z-P.; Gao X-M.; T cell vaccination in systemic lupus erythematosus with autologous activated T cells. Lupus  2005,14(11),884-889","journal-title":"Lupus"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/rheumatology\/kem369","volume":"47","author":"Mould A.W.","year":"2007","unstructured":"Mould A.W.; Scotney P.; Greco S.A.; Hayward N.K.; Nash A.; Kay G.F.; Prophylactic but not therapeutic activity of a monoclonal antibody that neutralizes the binding of VEGF-B to VEGFR-1 in a murine collagen-induced arthritis model. Rheumatology (Oxford)  2007,47(3),263-266","journal-title":"Rheumatology (Oxford)"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","volume":"33","author":"Curtis J.R.","year":"2011","unstructured":"Curtis J.R.; Singh J.A.; Use of biologics in rheumatoid arthritis: Current and emerging paradigms of care. Clin Ther  2011,33(6),679-707","journal-title":"Clin Ther"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3109\/s10165-006-0495-1","volume":"16","author":"Ohnishi Y.","year":"2006","unstructured":"Ohnishi Y.; Tsutsumi A.; Matsumoto I.; Goto D.; Ito S.; Kuwana M.; Uemura Y.; Nishimura Y.; Sumida T.; Altered peptide ligands control type II collagen-reactive T cells from rheumatoid arthritis patients. Mod Rheumatol  2006,16(4),226-228","journal-title":"Mod Rheumatol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2172-4-2","volume":"4","author":"Pedotti R.","year":"2003","unstructured":"Pedotti R.; Sanna M.; Tsai M.; DeVoss J.; Steinman L.; McDevitt H.; Galli S.J.; Severe anaphylactic reactions to glutamic acid decarboxylase (GAD) self peptides in NOD mice that spontaneously develop autoimmune type 1 diabetes mellitus. BMC Immunol  2003,4(1),2","journal-title":"BMC Immunol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/854954","volume":"2014","author":"Feng G.","year":"2014","unstructured":"Feng G.; Xue X.; Gao M.; Wang X.; Shu Z.; Mu N.; Gao Y.; Wang Z.; Hao Q.; Li W.; Li M.; Zhang C.; Zhang W.; Zhang Y.; Therapeutic effects of PADRE-BAFF autovaccine on rat adjuvant arthritis. BioMed Res Int  2014,2014,1-9","journal-title":"BioMed Res Int"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1073\/pnas.0400061101","volume":"101","author":"Prakken B.J.","year":"2004","unstructured":"Prakken B.J.; Samodal R.; Le T.D.; Giannoni F.; Yung G.P.; Scavulli J.; Amox D.; Roord S.; de Kleer I.; Bonnin D.; Lanza P.; Berry C.; Massa M.; Billetta R.; Albani S.; Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci USA  2004,101(12),4228-4233","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1002\/art.24566","volume":"60","author":"Hasselberg A.","year":"2009","unstructured":"Hasselberg A.; Sch&#xF6;n K.; Tarkowski A.; Lycke N.; Role of CTA1R7K-COL-DD as a novel therapeutic mucosal tolerance-inducing vector for treatment of collagen-induced arthritis. Arthritis Rheum  2009,60(6),1672-1682","journal-title":"Arthritis Rheum"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jim.2005.06.017","volume":"304","author":"Nandakumar K.S.","year":"2005","unstructured":"Nandakumar K.S.; Holmdahl R.; Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis. J Immunol Methods  2005,304(1-2),126-136","journal-title":"J Immunol Methods"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.intimp.2009.12.016","volume":"10","author":"Zimmerman D.H.","year":"2010","unstructured":"Zimmerman D.H.; Taylor P.; Bendele A.; Carambula R.; Duzant Y.; Lowe V.; O\u2019Neill S.P.; Talor E.; Rosenthal K.S.; CEL-2000: A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine\/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model. Int Immunopharmacol  2010,10(4),412-421","journal-title":"Int Immunopharmacol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1002\/art.10328","volume":"46","author":"Luross J.A.","year":"2002","unstructured":"Luross J.A.; Heaton T.; Hirst T.R.; Day M.J.; Williams N.A.; Escherichia coli heat-labile enterotoxin B subunit prevents autoimmune arthritis through induction of regulatory CD4+ T cells. Arthritis Rheum  2002,46(6),1671-1682","journal-title":"Arthritis Rheum"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.4049\/jimmunol.181.4.2741","volume":"181","author":"Kochetkova I.","year":"2008","unstructured":"Kochetkova I.; Trunkle T.; Callis G.; Pascual D.W.; Vaccination without autoantigen protects against collagen II-induced arthritis via immune deviation and regulatory T cells. J Immunol  2008,181(4),2741-2752","journal-title":"J Immunol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"5831","DOI":"10.37285\/ijpsn.2022.15.2.1","volume":"15","author":"Medhi B.","year":"2022","unstructured":"Medhi B.; Pahwa P.; Nanovaccine: Current status. International Journal of Pharmaceutical Sciences and Nanotechnology  2022,15(2),5831-5833","journal-title":"International Journal of Pharmaceutical Sciences and Nanotechnology"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"12530","DOI":"10.1002\/jcp.28120","volume":"234","author":"Gheibi Hayat S.M.","year":"2019","unstructured":"Gheibi Hayat S.M.; Darroudi M.; Nanovaccine: A novel approach in immunization. J Cell Physiol  2019,234(8),12530-12536","journal-title":"J Cell Physiol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actbio.2020.03.020","volume":"108","author":"Bhardwaj P.","year":"2020","unstructured":"Bhardwaj P.; Bhatia E.; Sharma S.; Ahamad N.; Banerjee R.; Advancements in prophylactic and therapeutic nanovaccines. Acta Biomater  2020,108,1-21","journal-title":"Acta Biomater"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.nano.2016.09.001","volume":"13","author":"Wang L.","year":"2017","unstructured":"Wang L.; Chang T.Z.; He Y.; Kim J.R.; Wang S.; Mohan T.; Berman Z.; Tompkins S.M.; Tripp R.A.; Compans R.W.; Champion J.A.; Wang B.Z.; Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity. Nanomedicine  2017,13(1),253-262","journal-title":"Nanomedicine"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ymeth.2013.04.014","volume":"60","author":"Zaman M.","year":"2013","unstructured":"Zaman M.; Good M.F.; Toth I.; Nanovaccines and their mode of action. Methods  2013,60(3),226-231","journal-title":"Methods"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.3390\/pharmaceutics13122091","volume":"13","author":"Cordeiro A.S.","year":"2021","unstructured":"Cordeiro A.S.; Patil-Sen Y.; Shivkumar M.; Patel R.; Khedr A.; Elsawy M.A.; Nanovaccine delivery approaches and advanced delivery systems for the prevention of viral infections: From development to clinical application. Pharmaceutics  2021,13(12),2091","journal-title":"Pharmaceutics"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.copbio.2012.05.004","volume":"23","author":"Casa&#xF1;as A.","year":"2012","unstructured":"Casa&#xF1;as A.; Guerra P.; Fita I.; Verdaguer N.; Vault particles: A new generation of delivery nanodevices. Curr Opin Biotechnol  2012,23(6),972-977","journal-title":"Curr Opin Biotechnol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/vaccines5010003","volume":"5","author":"Jiang J.","year":"2017","unstructured":"Jiang J.; Liu G.; Kickhoefer V.; Rome L.; Li L.X.; McSorley S.; Kelly K.; A protective vaccine against chlamydia genital infection using vault nanoparticles without an added adjuvant. Vaccines (Basel)  2017,5(1),3","journal-title":"Vaccines (Basel)"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1038\/s41467-019-11157-1","volume":"10","author":"Liu W.L.","year":"2019","unstructured":"Liu W.L.; Zou M.Z.; Liu T.; Zeng J.Y.; Li X.; Yu W.Y.; Li C.X.; Ye J.J.; Song W.; Feng J.; Zhang X.Z.; Cytomembrane nanovaccines show therapeutic effects by mimicking tumor cells and antigen presenting cells. Nat Commun  2019,10(1),3199","journal-title":"Nat Commun"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1208\/s12248-014-9707-3","volume":"17","author":"Trent A.","year":"2015","unstructured":"Trent A.; Ulery B.D.; Black M.J.; Barrett J.C.; Liang S.; Kostenko Y.; David N.A.; Tirrell M.V.; Peptide amphiphile micelles self-adjuvant group A streptococcal vaccination. AAPS J  2015,17(2),380-388","journal-title":"AAPS J"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1002\/adma.201200209","volume":"24","author":"Black M.","year":"2012","unstructured":"Black M.; Trent A.; Kostenko Y.; Lee J.S.; Olive C.; Tirrell M.; Self- assembled peptide amphiphile micelles containing a cytotoxic T- cell epitope promote a protective immune response in vivo. Adv Mater  2012,24(28),3845-3849","journal-title":"Adv Mater"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1016\/j.bmc.2016.07.036","volume":"24","author":"Hussein W.M.","year":"2016","unstructured":"Hussein W.M.; Liu T.Y.; Jia Z.; McMillan N.A.J.; Monteiro M.J.; Toth I.; Skwarczynski M.; Multiantigenic peptide-polymer conjugates as therapeutic vaccines against cervical cancer. Bioorg Med Chem  2016,24(18),4372-4380","journal-title":"Bioorg Med Chem"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jconrel.2010.03.027","volume":"145","author":"Henriksen-Lacey M.","year":"2010","unstructured":"Henriksen-Lacey M.; Christensen D.; Bramwell V.W.; Lindenstr&#xF8;m T.; Agger E.M.; Andersen P.; Perrie Y.; Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response. J Control Release  2010,145(2),102-108","journal-title":"J Control Release"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jconrel.2012.07.012","volume":"164","author":"Kaur R.","year":"2012","unstructured":"Kaur R.; Bramwell V.W.; Kirby D.J.; Perrie Y.; Manipulation of the surface pegylation in combination with reduced vesicle size of cationic liposomal adjuvants modifies their clearance kinetics from the injection site, and the rate and type of T cell response. J Control Release  2012,164(3),331-337","journal-title":"J Control Release"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.colsurfb.2009.06.025","volume":"74","author":"Badiee A.","year":"2009","unstructured":"Badiee A.; Jaafari M.R.; Khamesipour A.; Samiei A.; Soroush D.; Kheiri M.T.; Barkhordari F.; McMaster W.R.; Mahboudi F.; Enhancement of immune response and protection in BALB\/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): The role of bilayer composition. Colloids Surf B Biointerfaces  2009,74(1),37-44","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.exppara.2012.09.001","volume":"132","author":"Badiee A.","year":"2012","unstructured":"Badiee A.; Khamesipour A.; Samiei A.; Soroush D.; Shargh V.H.; Kheiri M.T.; Barkhordari F.; Robert Mc Master W.; Mahboudi F.; Jaafari M.R.; The role of liposome size on the type of immune response induced in BALB\/c mice against leishmaniasis: rgp63 as a model antigen. Exp Parasitol  2012,132(4),403-409","journal-title":"Exp Parasitol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1002\/anie.201804067","volume":"58","author":"Barriga H.M.G.","year":"2019","unstructured":"Barriga H.M.G.; Holme M.N.; Stevens M.M.; Cubosomes: The next generation of smart lipid nanoparticles? Angew Chem Int Ed  2019,58(10),2958-2978","journal-title":"Angew Chem Int Ed"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"771-81","DOI":"10.2147\/IJN.S8428","author":"Zhang XD.","year":"2010","unstructured":"Zhang XD.; Wu HY.; Wu D.; Toxicologic effects of gold nanoparticles in vivo by different administration routes. Int J Nanomedicine  2010(Sep),771-81","journal-title":"Int J Nanomedicine"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ejps.2011.10.012","volume":"44","author":"Wang T.","year":"2011","unstructured":"Wang T.; Zou M.; Jiang H.; Ji Z.; Gao P.; Cheng G.; Synthesis of a novel kind of carbon nanoparticle with large mesopores and macropores and its application as an oral vaccine adjuvant. Eur J Pharm Sci  2011,44(5),653-659","journal-title":"Eur J Pharm Sci"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1021\/nn200182x","volume":"5","author":"Villa C.H.","year":"2011","unstructured":"Villa C.H.; Dao T.; Ahearn I.; Fehrenbacher N.; Casey E.; Rey D.A.; Korontsvit T.; Zakhaleva V.; Batt C.A.; Philips M.R.; Scheinberg D.A.; Single-walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor-associated antigens. ACS Nano  2011,5(7),5300-5311","journal-title":"ACS Nano"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.tibtech.2022.03.011","volume":"40","author":"Azharuddin M.","year":"2022","unstructured":"Azharuddin M.; Zhu G.H.; Sengupta A.; Hinkula J.; Slater N.K.H.; Patra H.K.; Nano toolbox in immune modulation and nanovaccines. Trends Biotechnol  2022,40(10),1195-1212","journal-title":"Trends Biotechnol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/imr.12432","volume":"272","author":"Alloatti A.","year":"2016","unstructured":"Alloatti A.; Kotsias F.; Magalhaes J.G.; Amigorena S.; Dendritic cell maturation and cross-presentation: Timing matters! Immunol Rev  2016,272(1),97-108","journal-title":"Immunol Rev"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1021\/bm0503221","volume":"6","author":"Jain S.","year":"2005","unstructured":"Jain S.; Yap W.T.; Irvine D.J.; Synthesis of protein-loaded hydrogel particles in an aqueous two-phase system for coincident antigen and CpG oligonucleotide delivery to antigen-presenting cells. Biomacromolecules  2005,6(5),2590-2600","journal-title":"Biomacromolecules"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/jbm.a.30833","volume":"79A","author":"Li M.","year":"2006","unstructured":"Li M.; Mondrinos M.J.; Chen X.; Gandhi M.R.; Ko F.K.; Lelkes P.I.; Co-electrospun poly(lactide- co -glycolide), gelatin, and elastin blends for tissue engineering scaffolds. J Biomed Mater Res A  2006,79A(4),963-973","journal-title":"J Biomed Mater Res A"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1136\/ard.2007.086843","volume":"67","author":"Fiehn C.","year":"2008","unstructured":"Fiehn C.; Kratz F.; Sass G.; M&#xFC;ller-Ladner U.; Neumann E.; Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis. Ann Rheum Dis  2008,67(8),1188-1191","journal-title":"Ann Rheum Dis"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s12274-018-2233-3","volume":"12","author":"Wang Q.","year":"2019","unstructured":"Wang Q.; Li Y.; Chen X.; Jiang H.; Zhang Z.; Sun X.; Optimized in vivo performance of acid-liable micelles for the treatment of rheumatoid arthritis by one single injection. Nano Res  2019,12(2),421-428","journal-title":"Nano Res"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"23595","DOI":"10.1021\/acsami.8b06236","volume":"10","author":"Fan Z.","year":"2018","unstructured":"Fan Z.; Li J.; Liu J.; Jiao H.; Liu B.; Anti-inflammation and joint lubrication dual effects of a novel hyaluronic acid\/curcumin nanomicelle improve the efficacy of rheumatoid arthritis therapy. ACS Appl Mater Interfaces  2018,10(28),23595-23604","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1039\/C7NR08430G","volume":"10","author":"Xu X.L.","year":"2018","unstructured":"Xu X.L.; Li W.S.; Wang X.J.; Du Y.L.; Kang X.Q.; Hu J.B.; Li S.J.; Ying X.Y.; You J.; Du Y.Z.; Endogenous sialic acid-engineered micelles: A multifunctional platform for on-demand methotrexate delivery and bone repair of rheumatoid arthritis. Nanoscale  2018,10(6),2923-2935","journal-title":"Nanoscale"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2147\/IJN.S3217","author":"Schluep T.","year":"2008","unstructured":"Schluep T.; Hwang ; Rodgers ; Oliver ; &#x3B1;-Methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy. Int J Nanomedicine  2008(Oct),359","journal-title":"Int J Nanomedicine"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"5036","DOI":"10.1021\/acsnano.9b01710","volume":"13","author":"Liu L.","year":"2019","unstructured":"Liu L.; Hu F.; Wang H.; Wu X.; Eltahan A.S.; Stanford S.; Bottini N.; Xiao H.; Bottini M.; Guo W.; Liang X.J.; Secreted protein acidic and rich in cysteine mediated biomimetic delivery of methotrexate by albumin-based nanomedicines for rheumatoid arthritis therapy. ACS Nano  2019,13(5),5036-5048","journal-title":"ACS Nano"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"97","DOI":"10.7150\/thno.16844","volume":"7","author":"Yang M.","year":"2017","unstructured":"Yang M.; Ding J.; Feng X.; Chang F.; Wang Y.; Gao Z.; Zhuang X.; Chen X.; Scavenger receptor-mediated targeted treatment of collagen-induced arthritis by dextran sulfate-methotrexate prodrug. Theranostics  2017,7(1),97-105","journal-title":"Theranostics"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"20304","DOI":"10.1021\/acsami.8b22693","volume":"11","author":"Ren H.","year":"2019","unstructured":"Ren H.; He Y.; Liang J.; Cheng Z.; Zhang M.; Zhu Y.; Hong C.; Qin J.; Xu X.; Wang J.; Role of liposome size, surface charge, and PEGylation on rheumatoid arthritis targeting therapy. ACS Appl Mater Interfaces  2019,11(22),20304-20315","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.biomaterials.2015.05.018","volume":"61","author":"Kim H.J.","year":"2015","unstructured":"Kim H.J.; Lee S.M.; Park K.H.; Mun C.H.; Park Y.B.; Yoo K.H.; Drug-loaded gold\/iron\/gold plasmonic nanoparticles for magnetic targeted chemo-photothermal treatment of rheumatoid arthritis. Biomaterials  2015,61,95-102","journal-title":"Biomaterials"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jconrel.2018.05.035","volume":"283","author":"Aldayel A.M.","year":"2018","unstructured":"Aldayel A.M.; O\u2019Mary H.L.; Valdes S.A.; Li X.; Thakkar S.G.; Mustafa B.E.; Cui Z.; Lipid nanoparticles with minimum burst release of TNF-&#x3B1; siRNA show strong activity against rheumatoid arthritis unresponsive to methotrexate. J Control Release  2018,283,280-289","journal-title":"J Control Release"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.ymthe.2019.05.002","volume":"27","author":"Song P.","year":"2019","unstructured":"Song P.; Yang C.; Thomsen J.S.; Dagn&#xE6;s-Hansen F.; Jakobsen M.; Br&#xFC;el A.; Deleuran B.; Kjems J.; Lipidoid-siRNA nanoparticle- mediated IL-1&#x3B2; gene silencing for systemic arthritis therapy in a mouse model. Mol Ther  2019,27(8),1424-1435","journal-title":"Mol Ther"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.1039\/C9BM01025D","volume":"7","author":"Zhao G.","year":"2019","unstructured":"Zhao G.; Liu A.; Zhang Y.; Zuo Z.Q.; Cao Z.T.; Zhang H.B.; Xu C.F.; Wang J.; Nanoparticle-delivered siRNA targeting Bruton\u2019s tyrosine kinase for rheumatoid arthritis therapy. Biomater Sci  2019,7(11),4698-4707","journal-title":"Biomater Sci"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1021\/bc500427g","volume":"25","author":"Byeon H.J.","year":"2014","unstructured":"Byeon H.J.; Min S.Y.; Kim I.; Lee E.S.; Oh K.T.; Shin B.S.; Lee K.C.; Youn Y.S.; Human serum albumin-TRAIL conjugate for the treatment of rheumatoid arthritis. Bioconjug Chem  2014,25(12),2212-2221","journal-title":"Bioconjug Chem"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1021\/nn500685h","volume":"8","author":"Lee H.","year":"2014","unstructured":"Lee H.; Lee M.Y.; Bhang S.H.; Kim B.S.; Kim Y.S.; Ju J.H.; Kim K.S.; Hahn S.K.; Hyaluronate-gold nanoparticle\/tocilizumab complex for the treatment of rheumatoid arthritis. ACS Nano  2014,8(5),4790-4798","journal-title":"ACS Nano"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.clim.2014.01.005","volume":"151","author":"Vanniasinghe A.S.","year":"2014","unstructured":"Vanniasinghe A.S.; Manolios N.; Schibeci S.; Lakhiani C.; Kamali-Sarvestani E.; Sharma R.; Kumar V.; Moghaddam M.; Ali M.; Bender V.; Targeting fibroblast-like synovial cells at sites of inflammation with peptide targeted liposomes results in inhibition of experimental arthritis. Clin Immunol  2014,151(1),43-54","journal-title":"Clin Immunol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.actbio.2015.05.036","volume":"24","author":"Korkmaz E.","year":"2015","unstructured":"Korkmaz E.; Friedrich E.E.; Ramadan M.H.; Erdos G.; Mathers A.R.; Burak Ozdoganlar O.; Washburn N.R.; Falo L.D.; Therapeutic intradermal delivery of tumor necrosis factor-alpha antibodies using tip-loaded dissolvable microneedle arrays. Acta Biomater  2015,24,96-105","journal-title":"Acta Biomater"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/pharmaceutics11050235","volume":"11","author":"Cao J.","year":"2019","unstructured":"Cao J.; Zhang N.; Wang Z.; Su J.; Yang J.; Han J.; Zhao Y.; Microneedle-assisted transdermal delivery of etanercept for rheumatoid arthritis treatment. Pharmaceutics  2019,11(5),235","journal-title":"Pharmaceutics"}],"container-title":["Current Rheumatology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115733971330575250121054355","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/240179\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115733971330575250121054355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T04:09:44Z","timestamp":1763611784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/240179\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":129,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115733971330575250121054355","relation":{},"ISSN":["1573-3971"],"issn-type":[{"type":"print","value":"1573-3971"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-06-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}